Quadrant Capital Group’s Larimar Therapeutics LRMR Stock Holding History

Quadrant Capital Group’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,976	Closed	-$8.89K	–	1993
2026 Q1	$8.89K	Buy	1,976 +223	+13%	+$891	﹤0.01%	2219
2025 Q4	$6.68K	Buy	+1,753	New	+$6.82K	﹤0.01%	2305
2025 Q1	–	Sell	-14	Closed	-$55	–	2810
2024 Q4	$55	Sell	14 -356	-96%	-$2.35K	﹤0.01%	2728
2024 Q3	$2.42K	Buy	+370	New	+$2.97K	﹤0.01%	2467
2019 Q2	–	Sell	-137	Closed	-$4K	–	2370
2019 Q1	$4K	Hold	137	–	–	﹤0.01%	1923
2018 Q4	$8K	Hold	137	–	–	﹤0.01%	1469
2018 Q3	$19K	Hold	137	–	–	0.01%	1011
2018 Q2	$16K	Hold	137	–	–	0.01%	1065
2018 Q1	$12K	Hold	137	–	–	﹤0.01%	1178
2017 Q4	$7K	Hold	137	–	–	﹤0.01%	1345
2017 Q3	$5K	Hold	137	–	–	﹤0.01%	1476
2017 Q2	$5K	Hold	137	–	–	﹤0.01%	1353
2017 Q1	$7K	Hold	137	–	–	﹤0.01%	1215
2016 Q4	$5K	Buy	+137	New	+$5.56K	﹤0.01%	1245

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Quadrant Capital Group's LRMR Position: Q2 2026 in Review

Quadrant Capital Group sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 1,976 shares — an estimated $8.89K sold.

Quadrant Capital Group first reported a position in LRMR in Q4 2016 and held it in 14 quarters. The position peaked at $19K in Q3 2018. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Quadrant Capital Group reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 1,976 Larimar Therapeutics shares in Q2 2026, an estimated $8.89K.
Quadrant Capital Group first reported a position in Larimar Therapeutics in Q4 2016 and held it in 14 quarters.
Quadrant Capital Group's Larimar Therapeutics position peaked at $19K in Q3 2018.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.